Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference52 articles.
1. Lunn, M. R., & Wang, C. H. (2008). Spinal muscular atrophy. The Lancet, 371(9630), 2120–2133.
2. Finkel, R. S., et al. (2016). Treatment of infantile-onset spinal muscular atrophy with Nusinersen: A phase 2, open-label, dose-escalation study. The Lancet, 388(10063), 3017–3026.
3. Luan, X., et al. (2016). Infantile spinal muscular atrophy with respiratory distress type I presenting without respiratory involvement: Novel mutations and review of the literature. Brain Development, 38(7), 685–689.
4. European Medicines Agency. (2017). Spinraza. Retrieved August 07, 2017, from
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004312/human_med_002119.jsp&mid=WC0b01ac058001d124
.
5. Kocova, H., et al. (2014). Health-related quality of life in children and adolescents with spinal muscular atrophy in the Czech Republic. Pediatric Neurology, 50(6), 591–594.
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献